Winter Health Wellness: Rheumatoid fear “Cold Wind” – winter health regimen – the pharmaceutical industries
Interviewed experts / Guangzhou Medicine University, Division of Rheumatology, First Affiliated Hospital Director Professor Lin Changsong
Cold hit, cold wind whizzing. Patients with rheumatoid arthritis at this time the most painful, because the “Cold Wind” is the acute attack of rheumatoid arthritis, an important incentive. “Last month was more than an empty bed, now 45 beds all full, had to bed, out-patients also increased.” Guangzhou University of Traditional Chinese Medicine Division of Rheumatology, First Affiliated Hospital Director Professor Lin Changsong, said: “Patients with rheumatoid arthritis particularly sensitive to the weather, the cooling time paying particular attention to warm, to prevent exacerbations.
“Cold Wind” is the main cause
Chinese rheumatoid arthritis is referred to as “Bi Syndrome.” Chinese medicine, “Cold Wind to three gas hybrid, co-Stagnation also.” Patients are often manifested as muscle and joint swelling, joint pain, cold area with obvious feeling, serious illness, even in the summer will feel aversion to cold fear cold, for cold and rainy weather were symptoms worsened during warm bath or relieve symptoms after baking.
Experts say people who work in the field a long time, year-round work of the office girl in the office every day in air-conditioned environment, and there are wearing dresses, these people suffer from rheumatoid arthritis disease is easily repeated, increasing.
Many patients do not diet in rheumatoid
Always thought a lot of rheumatic disease diet after the numerous taboos, animal offal can not eat, can not eat seafood, do not even eat eggs. Linzhu Ren said: “In fact, this is a misunderstanding. In addition to
Gouty arthritis , Other rheumatic most do not have taboos, especially in patients with rheumatoid arthritis, their poor physical condition, many patients with
Anemia Hypoproteinemia, this population if a balanced diet, poor nutrition, and disease more difficult to restore. ”
Course, some patients with rheumatoid arthritis, immune state of disorder, for some drugs or foods are often more sensitive than normal, these patients may be very clear about what foods to eat after the pain will be significantly increased, it should be “diet “do not eat these foods. In addition, other food can eat, high protein food, rich in
Vitamin Fresh fruits and vegetables can not be less.
Prescription Care Exercise appropriately increase activities to smooth the meridians, qi and blood circulation, enhance immunity in patients with rheumatoid arthritis and maintain joint function.
bed movement: In the acute stage to reduce the weight-bearing exercise, can do some of the bed extension activities in order to maintain joint function. The remission Zexu regular activities. Of disease activity in some patients because of joint pain and completely inactive, the results appeared to be after the inflammation subsided muscle, ligament adhesions, resulting in significant obstacles to joint function, affecting the rehabilitation of joints. Therefore, joint pain patients may wish to slow in bed doing stretching exercises, such as are joint or muscle stiffness, may be in the sports massage before.
massage rub: rheumatoid arthritis patients vulnerable to hand-foot-cold, cold weather, these parts more easily catch cold. Chinese medicine, Yin and Yang meridians by the other 12 multi-intersection in the index finger, often rubbing blood meridian massage is not only beneficial to smooth, warm cold, can also help relieve rheumatoid arthritis hand swelling, early morning knuckles rigid symptoms.
warm water foot bath: As the saying goes, cold starting from the feet. Patients with rheumatoid arthritis foot bath with hot water every night before going to bed half an hour, side foam side twist, not only can promote blood circulation, but also improve sleep.
Diet Diet Number of patients with rheumatoid arthritis can choose food and medicine homologous
Traditional Chinese medicine Since Pharmacy Diet to enhance physical fitness, reduce disease.
Smilax water snake chicken soup
Material: Water Snake (or Banyan snake) 250 grams, 50 grams of Smilax glabra, Chixiaodou 50 grams, ginger 20 grams, 100 grams of chicken.
check out these aged people healthcare products
Permanent Hemorrhoid Cure
Discover A Simple And Easy Way To Cure Your Hemorrhoids. Natural, Safe Hemorrhoids Treatment That Helps To Avoid Hemorrhoids Surgery. Get Rid Of Your Hemorrhoids And Get Your Life Back!
Permanent Hemorrhoid Cure
Treat Leaky Gut Syndrome And Re-discover Your Health.
Leaky Gut Syndrome Is The One Condition That Is Responsible For A Multitude Of Debilitating Diseases. Understanding This Common Condition Is The Key To Total Health And Wellbeing. Read How I Keep MS Condition Totally Under Control.
Treat Leaky Gut Syndrome And Re-discover Your Health.
India Pharmaceuticals & Healthcare Report
The India Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end-2014 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments. ( http://www.bharatbook.com/detail.asp?id=6835&rt=India-Pharmaceuticals-Healthcare-Report.html )
India Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.
Key Benefits of Report
* Benchmark Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on India to test other views – a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
* Target Business Opportunities & Risks in the Indian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in India.
* Exploit The Latest Competitive Indian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in India.
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets.
The SWOT outlines strategic factors which affect forecast analysis, and taken together with Economic and Business Environment SWOTS, give a complete overview of market climate.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=6835&rt=India-Pharmaceuticals-Healthcare-Report.html
Pharmaceuticals: Global Industry Guide
Global Healthcare Information Technology (2009 – 2014)
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Bharat Book Bureau, the leading market research information aggregator provides reports, company profiles, newsletters, country info. and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our reports help global companies to know different market before starting up business / expanding in different countries across the world.
Vision Shopsters: Australia Pharmaceutical Market Overview – Reforms and continued price cuts will change the healthcare landscape
The prescription pharmaceutical market in Australia was valued at $ 9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.
*Overview of Australia’s socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.
*Assesses the size of Australia’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.
*Examines Australia’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.
*Quantifies Australia’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.
Australia’s health expenditure totaled $ 81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 200708, which is the same percentage of GDP as the previous year. Australia’s health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($ 550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.
Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia’s biosimilar market is small, particularly in terms of sales at $ 45,000.
Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.
Reasons to Purchase
*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
*Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.
*Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.
To know more about this report & to buy a copy please visit :
Visionshopsters expertise in providing comprehensive collection of online market research reports, events, seminars bookings, country reports, company profiles, latest books and magazines, customized research services offering informative solutions worldwide.
In March of this year President Obama signed the Patient Protection and Affordable Care Act into law. This is a piece of legislation that authorizes the FDA to implement a shortened approval process for biological products biosimilar to previously approved biological medicines. The ground to be crossed toward approval looks to be rough and hazard strewn. Pharmaceutical consultants may prove to be a valuable asset in guiding companies through this apparently thorny regulatory tangle.
The aim of this legislation is, apparently, the same as similar legislation for generics— that is, to produce and improve access to cheaper drugs and thus to lighten the financial burden for both patients and the healthcare industry. The problem, though, is that there are likely to be far more testing and regulatory complications.
Generic drugs are exact chemical copies of brand-name drugs.
A biosimilar, however, is not identical to the brand-name product. Biosimilars are made up of large, often complex proteins produced inside living cells, and very slight differences can produce widely divergent reactions in patients. Therefore, the regulatory approval process a biosimilar has to go through is far more complicated than for a generic and involves human clinical trials as well.
Among industry analysts, the fear on the economic side has been that this legislation, when passed, would look far too much like the Hatch-Waxman Act of 1984, which set the stage for the current generic industry. In that scenario, both the “make-hay” and the “blockbuster” effect would be exacerbated. Smaller companies and start-ups would then, in effect, be nudged out of the competitive picture.
The so-called “make-hay” effect, which came into being after Hatch-Waxman took effect, describes the phenomenon of pharmaceutical companies’ having to make as much money as soon as they can after introducing a new drug. This means that they usually have to raise prices and invest more in marketing and less in innovation. The “blockbuster” effect, most are familiar with. After Hatch-Waxman, companies had to concentrate on bringing to market drugs that had either high patient populations or high value. There appears to be fertile ground here for pharmaceutical consultants to assist drug companies in growing competitiveness and raising profitability.
In early November, representatives from various segments of the drug industry met at the FDA headquarters in Rockville, MD, to hammer out ways to implement and regulate the still inchoate regulatory pathway for follow-on biologic medications (biosimilars). During this important discussion among representatives from pharmaceuticals, generics, and biotechnology, a few common threads could be picked out.
For example, Sara Radcliffe, BIO Executive Vice President – Health, emphasized patient safety and innovation incentives. Similarly, Marie Vodicka, PhRMA’s Associate Vice President for Scientific and Regulatory Affairs, pressed for ensuring patient access to safe biosimilars, creating a science-based approval pathway involving a transparent process, and encouraging innovation and competition. And Joe Militech, Amgen’s Senior Vice President of R&D, averred, “Put patients first and sound policy will follow. . . . The question before the agency is how we can minimize patient risk and uncertainty associated with the approval of biosimilars.” This seems, then, a pretty clear indication of where things are headed and suggests a growing role for pharmaceutical consulting.
New ground is opening up now in the area of biosimilars in the US. And it can be profitably fertile ground when pharmaceutical companies and pharmaceutical consultants meet on it.
Hiring Smart Consulting Group for your Pharma Consultant needs is like having your own ‘insiders’ expert team.
We help Pharma companies gain the competitive edge they need to be the market leaders in pharmaceutical and medical device products. Smart Consulting Group focuses on the delivery of lean, efficient, cost effective work product without sacrificing technical capability or regulatory compliance. Call us so we can apply our winning strategy to your situation.